3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Colorectal Neoplasms
3
Neoplasms
2
Lung Neoplasms
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Melanoma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Esophageal Squamous Cell Carcinoma
1
EGFR-mutant Non-small Cell Lung Cancer
1
Adenocarcinoma of Lung
1
Interventions
Pemetrexed
40
Cisplatin
35
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Drug Therapy
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Oxaliplatin
3
Imatinib Mesylate
3
Fluorouracil
3
Cerebral Decortication
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
ribociclib
×
Thoracic
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts